Baird raised the firm’s price target on Enliven (ELVN) to $40 from $32 and keeps an Outperform rating on the shares. The firm said they reported 3Q24 results and notably, the company recently reported new ELVN-001 data, showing compelling efficacy and safety in CML. A meaningful update from this trial is on track for 2025.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio